Rate My Professor Zhibin Cui

Employing cutting-edge methodologies like high-throughput CRISPRi screening, next-generation sequencing, tissue engineering, preclinical mouse tumor models, transgenic mutation knock-in models, and clinical patient sample analyses, Cui seeks to uncover novel therapeutic targets for advanced, treatment-resistant HNSCC. His work also delves into immunotherapy mechanisms, cancer cell-death pathways like pyroptosis, and the role of high-frequency genetic mutations in the malignant transformation of oral epithelium. Cui maintains a robust publication record, featuring contributions to high-impact journals such as Cell Death and Disease, Molecular Cancer Research, Biomolecules, and Frontiers in Immunology. Representative publications include "Triggering Pyroptosis in Cancer" (2025, Biomolecules) and "Sarcomatoid carcinoma transformation in oral undifferentiated carcinoma" (2024, Frontiers in Immunology). A recipient of the Tobacco-Related Disease Research Program (TRDRP) postdoctoral fellowship, he leads the Cui Lab, which conducts translational research in gene therapy, genome-wide screening, immunology, molecular genetics, genomics, and head and neck oncology. His efforts are poised to advance therapeutic options for therapy-resistant head and neck cancers.